Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM185PE | TNBC | Luminal | Doxorubicin | TOP2 | TOP | 0.736 | uM | 10146.121 | 0.4339 | -0.1146 | 1.0246 | |
| SUM185PE | TNBC | Luminal | Doxorubicin | TOP2 | TOP | 3.68 | uM | 10146.121 | 0.3222 | -0.3378 | 1.0246 | |
| SUM185PE | TNBC | Luminal | Doxorubicin | TOP2 | TOP | 18.4 | uM | 10146.121 | 0.2748 | -0.4332 | 1.0246 | |
| SUM185PE | TNBC | Luminal | Doxorubicin | TOP2 | TOP | 92 | uM | 10146.121 | 0.0212 | -0.9534 | 1.0246 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 7536.078 | 0.9899 | 0.9826 | 1.1676 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 7536.078 | 1.0441 | 1.0753 | 1.1676 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 7536.078 | 1.0108 | 1.0185 | 1.1676 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 7536.078 | 1.0589 | 1.1005 | 1.1676 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.147 | uM | 7536.078 | 0.8357 | 0.7151 | 1.1676 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.736 | uM | 7536.078 | 0.2579 | -0.3734 | 1.1676 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 3.68 | uM | 7536.078 | 0.2570 | -0.3753 | 1.1676 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 18.4 | uM | 7536.078 | 0.2519 | -0.3858 | 1.1676 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 92 | uM | 7536.078 | 0.2067 | -0.4815 | 1.1676 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 9860.121 | 1.0026 | 1.0030 | 1.7546 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 9860.121 | 0.9611 | 0.9553 | 1.7546 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9860.121 | 1.0347 | 1.0392 | 1.7546 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9860.121 | 0.9318 | 0.9211 | 1.7546 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9860.121 | 0.7713 | 0.7249 | 1.7546 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9860.121 | 0.2813 | -0.0293 | 1.7546 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9860.121 | 0.3172 | 0.0396 | 1.7546 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9860.121 | 0.2664 | -0.0590 | 1.7546 | |
| SUM229PE | TNBC | - | Doxorubicin | TOP2 | TOP | 92 | uM | 9860.121 | 0.1416 | -0.3436 | 1.7546 | |
| SUM44PE | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 7538.078 | 0.9072 | 0.7890 | 0.8734 | |
| SUM44PE | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 7538.078 | 1.0265 | 1.0607 | 0.8734 | |
| SUM44PE | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 7538.078 | 1.0082 | 1.0188 | 0.8734 |